Who
Sanjay R. Singh
EVP Technical Operations
Company insider
Files Form 4 as: EVP Technical Operations, MannKind.
In numbers
- Trades disclosed
- 30
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $94K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Nov 2022
- Last trade
- 15 Jul 2026
- Last filed
- 17 Jul 2026
Companies traded
Activity over time
1 Nov 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code M | —70,550 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $90K22,047 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $22K5,372 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —70,550 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $41K10,079 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $38K9,297 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —70,550 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code M | —70,550 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $90K22,047 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $22K5,372 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $41K10,079 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $38K9,297 at $4.09 | filing |
| 23 Mar 2026filed 25 Mar 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —221,000 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —217,000 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —221,000 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —217,000 at $0.00 | filing |
| 14 Nov 2025filed 14 Nov 2025 | MNKD MannKindPharmaceuticals | SEC FORM 4 Sold | $94K18,777 at $5.03 | filing |
| 31 Oct 2025filed 3 Nov 2025 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $95K17,071 at $5.59 | filing |
| 15 Jul 2025filed 17 Jul 2025 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $59K15,450 at $3.85 | filing |
| 13 May 2025filed 15 May 2025 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —145,000 at $0.00 | filing |
News
Comparing MannKind (NASDAQ:MNKD) & Iovance Biotherapeutics (NASDAQ:IOVA)MNKD · tickerreport.com · 15 Oct 2026MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)MNKD · manilatimes.net · 10 Oct 2026
0 headlines in the last 90 days name Sanjay R. Singh; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.